article thumbnail

Cheryl Barton

pharmaphorum

In 2002, Dr Barton founded PharmaVision to provide independent, tailor-made, life sciences, and consumer health research to pharmaceutical companies, competitive intelligence specialists, investment institutions, and healthcare communication agencies.

article thumbnail

Personalizing the Cancer Patient Journey

Pharma Marketing Network

Communication needs to be welcoming, relevant, and digestible. Patient centricity is informed by empathy and an understanding of the patient journey and the many factors that affect the patient experience along the continuum. Personalization means the customer feels as if someone is speaking directly to them. Accessed June 18, 2022.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Speaking of Medicine – Mid-Year OPDP Enforcement Review

Eye on FDA

There are two means of gaining insight into the agency’s thinking about regulatory issues related to promotional communications by pharmaceutical companies; one is through the issuance of guidance documents, the other is through enforcement. But when it comes to enforcement things have changed greatly over the years.

article thumbnail

Porterhouse Medical Group joins imc group

pharmaphorum

Porterhouse Medical Group has joined up with imc (integrated medhealth communication) group, a healthcare communications and consulting agency. The post Porterhouse Medical Group joins imc group appeared first on.

article thumbnail

Healthware Group announces acquisition of Argon Global Healthcare network

pharmaphorum

” Established in 2002, Argon Global Healthcare has built a global healthcare agency network covering major markets in EMEA, Americas, and APAC. This robust network comprises independently owned healthcare communications agencies with a proven track record of high performance.

article thumbnail

Three strategies for managing loss of exclusivity successfully

pharmaphorum

6 The stakes were extremely high, with annual costs of insulin reaching $736 per patient in 2013, up threefold since 2002. RESULT: As of 2002, 40% of PRILOSEC patients had switched to NEXIUM, which notched up sales of $3.9 Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. billion in 2004.14

article thumbnail

Achieving scale up success under economic uncertainty

European Pharmaceutical Review

2 By comparison, the American Society of Health-System Pharmacists (ASHP) identified only 224 drug shortages during the entire six-year period between January 1996 and June 2002. Having an effective risk management model requires open communication, full transparency and speedy decision-making.